🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06990594
Starting soon Observational

A Multi-Center Bidirectional Cohort Study on Total Knee Arthroplasty for the Treatment of Knee Osteoarthritis

NCT06990594 · tracked via the Priya Life Science China tracker
Sponsor
Beijing Tsinghua Chang Gung Hospital
Phase
Observational
Started
2025-06-01
Last updated
2025-05-25

Condition(s) studied

Osteoarthritis

Study summary

The purpose of this study is to evaluate the clinical benefits of different types of total knee arthroplasty (TKA) in osteoarthritis treatment. The study aims to compare surgical outcomes, functional recovery, complication rates, and cost-effectiveness among personalized, semi-personalized, and conventional TKA in a multi-center, bidirectional cohort study.

Eligibility

Sex
ALL
Min age
50 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: 1. Patients aged 50-80 years. 2. Diagnosed with end-stage knee osteoarthritis, post-traumatic arthritis, avascular necrosis, or inflammatory arthritis requiring total knee arthroplasty. 3. Willing and able to provide informed consent. Exclusion Criteria: 1. History of prior knee surgery or knee replacement. 2. Severe knee deformity (valgus \>20° or varus \>15°) or instability. 3. Severe contracture (\>25° flexion contracture). 4. Undergoing total knee revision surgery. 5. Rheumatoid arthritis diagnosis. 6. BMI \>35. 7. Neuromuscular disorders affecting knee stability or gait. 8. Pregnancy or lactation. 9. Presence of significant comorbidities posing unacceptable risk. 10. Active or recent severe infections or malignancy. 11. History of drug or alcohol abuse in the past six months.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Beijing Tsinghua Chang Gung Hospital Beijing Beijing Municipality

More Beijing Tsinghua Chang Gung Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06990594 on ClinicalTrials.gov ↗ ← All trials in China